Loubani Osama M, Green Robert S
Departments of Critical Care Medicine and Emergency Medicine, Dalhousie University, Room 377, Bethune Building, 1276 South Park St, Halifax, Nova Scotia B3H 2Y9, Canada.
Departments of Critical Care Medicine and Emergency Medicine, Dalhousie University, Room 377, Bethune Building, 1276 South Park St, Halifax, Nova Scotia B3H 2Y9, Canada; Trauma Nova Scotia, 1276 South Park St, Centennial Building Room 1-026B, Halifax, Nova Scotia B3H 2Y9, Canada.
J Crit Care. 2015 Jun;30(3):653.e9-17. doi: 10.1016/j.jcrc.2015.01.014. Epub 2015 Jan 22.
The aim of this study was to collect and describe all published reports of local tissue injury or extravasation from vasopressor administration via either peripheral intravenous (IV) or central venous catheter.
A systematic search of Medline, Embase, and Cochrane databases was performed from inception through January 2014 for reports of adults who received vasopressor intravenously via peripheral IV or central venous catheter for a therapeutic purpose. We included primary studies or case reports of vasopressor administration that resulted in local tissue injury or extravasation of vasopressor solution.
Eighty-five articles with 270 patients met all inclusion criteria. A total of 325 separate local tissue injury and extravasation events were identified, with 318 events resulting from peripheral vasopressor administration and 7 events resulting from central administration. There were 204 local tissue injury events from peripheral administration of vasopressors, with an average duration of infusion of 55.9 hours (±68.1), median time of 24 hours, and range of 0.08 to 528 hours. In most of these events (174/204, 85.3%), the infusion site was located distal to the antecubital or popliteal fossae.
Published data on tissue injury or extravasation from vasopressor administration via peripheral IVs are derived mainly from case reports. Further study is warranted to clarify the safety of vasopressor administration via peripheral IVs.
本研究旨在收集并描述所有已发表的关于通过外周静脉或中心静脉导管给予血管升压药后发生局部组织损伤或外渗的报告。
对Medline、Embase和Cochrane数据库进行系统检索,检索时间从建库起至2014年1月,以查找通过外周静脉或中心静脉导管静脉给予血管升压药用于治疗目的的成人报告。我们纳入了导致局部组织损伤或血管升压药溶液外渗的血管升压药给药的原始研究或病例报告。
85篇文章涉及270例患者,均符合所有纳入标准。共识别出325例单独的局部组织损伤和外渗事件,其中318例事件由外周血管升压药给药引起,7例事件由中心给药引起。外周给予血管升压药导致204例局部组织损伤事件,平均输注持续时间为55.9小时(±68.1),中位时间为24小时,范围为0.08至528小时。在大多数这些事件中(174/204,85.3%),输注部位位于肘前或腘窝远端。
关于通过外周静脉给予血管升压药导致组织损伤或外渗的已发表数据主要来自病例报告。有必要进一步研究以阐明通过外周静脉给予血管升压药的安全性。